NASDAQ:ETRA

Electra Therapeutics Q3 2026 Earnings Results & Report

$9.00 +0.57 (+6.76%)
As of 02:27 PM Eastern

Electra Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$3.47 versus the -$1.76 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
4:00 PM ET

Electra Therapeutics EPS Results

Actual EPS
-$3.47
Consensus EPS
-$1.76
Beat/Miss
Missed by -$1.71
One Year Ago EPS
N/A

Electra Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Electra Therapeutics Q3 2026 Earnings FAQ

Electra Therapeutics (NASDAQ:ETRA) reported earnings of -$3.47 per share for Q3 2026, missing the consensus estimate of -$1.76. The report was announced on Thursday, November 12, 2026.

Electra Therapeutics Earnings Headlines

Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
Electra Therapeutics (NASDAQ:ETRA) Shares Down 9% After Earnings Miss
See More Electra Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Electra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Electra Therapeutics and other key companies, straight to your email.

About Electra Therapeutics

Electra Therapeutics (NASDAQ:ETRA) (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.

Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression. The product remains investigational and has not been approved for commercial use.

Electra Therapeutics is based in the United States and conducts its development activities through clinical research and collaboration with medical and scientific institutions. The company’s pipeline and geographic operations may evolve as its clinical programs advance.

View Electra Therapeutics Profile